{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:53:15Z","timestamp":1790823195307,"version":"4.1.0"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,18]],"date-time":"2019-12-18T00:00:00Z","timestamp":1576627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,12,18]],"date-time":"2019-12-18T00:00:00Z","timestamp":1576627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1007\/s40744-019-00189-0","type":"journal-article","created":{"date-parts":[[2019,12,18]],"date-time":"2019-12-18T13:02:52Z","timestamp":1576674172000},"page":"19-33","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":83,"title":["Autoimmunity and Inflammation Link to Cardiovascular Disease Risk in Rheumatoid Arthritis"],"prefix":"10.1007","volume":"7","author":[{"given":"Daniel J.","family":"DeMizio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura B.","family":"Geraldino-Pardilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,18]]},"reference":[{"issue":"1","key":"189_CR1","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jbspin.2012.02.005","volume":"80","author":"S Dadoun","year":"2013","unstructured":"Dadoun S, Zeboulon-Ktorza N, Combescure C, Elhai M, Rozenberg S, Gossec L, et al. Mortality in rheumatoid arthritis over the last fifty years: systematic review and meta-analysis. Jt Bone Spine. 2013;80(1):29\u201333.","journal-title":"Jt Bone Spine."},{"issue":"4","key":"189_CR2","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s00296-016-3638-5","volume":"37","author":"J van den Hoek","year":"2017","unstructured":"van den Hoek J, Boshuizen HC, Roorda LD, Tijhuis GJ, Nurmohamed MT, van den Bos GAM, et al. Mortality in patients with rheumatoid arthritis: a 15-year prospective cohort study. Rheumatol Int. 2017;37(4):487\u201393.","journal-title":"Rheumatol Int"},{"issue":"1","key":"189_CR3","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/acr.22642","volume":"68","author":"BR England","year":"2016","unstructured":"England BR, Sayles H, Michaud K, Caplan L, Davis LA, Cannon GW, et al. Cause-specific mortality in male US veterans with rheumatoid arthritis: veterans with RA and cause-specific mortality. Arthritis Care Res. 2016;68(1):36\u201345.","journal-title":"Arthritis Care Res"},{"issue":"5","key":"189_CR4","doi-asserted-by":"publisher","first-page":"360","DOI":"10.3109\/03009741003604542","volume":"39","author":"A Nakajima","year":"2010","unstructured":"Nakajima A, Inoue E, Tanaka E, Singh G, Sato E, Hoshi D, et al. Mortality and cause of death in Japanese patients with rheumatoid arthritis based on a large observational cohort. IORRA Scand J Rheumatol. 2010;39(5):360\u20137.","journal-title":"IORRA Scand J Rheumatol"},{"issue":"5 Suppl 51","key":"189_CR5","first-page":"S35","volume":"26","author":"T Sokka","year":"2008","unstructured":"Sokka T, Abelson B, Pincus T. Mortality in rheumatoid arthritis: 2008 update. Clin Exp Rheumatol. 2008;26(5 Suppl 51):S35\u201361.","journal-title":"Clin Exp Rheumatol"},{"issue":"12","key":"189_CR6","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1136\/ard.2005.050377","volume":"65","author":"DH Solomon","year":"2006","unstructured":"Solomon DH, Goodson NJ, Katz JN, Weinblatt ME, Avorn J, Setoguchi S, et al. Patterns of cardiovascular risk in rheumatoid arthritis. Ann Rheumatol Dis. 2006;65(12):1608\u201312.","journal-title":"Ann Rheumatol Dis"},{"issue":"4","key":"189_CR7","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1002\/art.1780370408","volume":"37","author":"F Wolfe","year":"1994","unstructured":"Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA, et al. The mortality of rheumatoid arthritis. Arthritis Rheumatol. 1994;37(4):481\u201394.","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"189_CR8","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1002\/art.24836","volume":"61","author":"MJL Peters","year":"2009","unstructured":"Peters MJL, van Halm VP, Voskuyl AE, Smulders YM, Boers M, Lems WF, et al. Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study. Arthritis Rheumatol. 2009;61(11):1571\u20139.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"189_CR9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1136\/annrheumdis-2016-209775","volume":"76","author":"R Agca","year":"2017","unstructured":"Agca R, Heslinga SC, Rollefstad S, Heslinga M, McInnes IB, Peters MJL, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015\/2016 update. Ann Rheumatol Dis. 2017;76(1):17\u201328.","journal-title":"Ann Rheumatol Dis"},{"issue":"5","key":"189_CR10","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1002\/acr.21935","volume":"65","author":"L Gossec","year":"2013","unstructured":"Gossec L, Salejan F, Nataf H, Nguyen M, Gaud-Listrat V, Hudry C, et al. Challenges of cardiovascular risk assessment in the routine rheumatology outpatient setting: an observational study of 110 rheumatoid arthritis patients: CV risk assessment in rheumatology clinics. Arthritis Care Res. 2013;65(5):712\u20137.","journal-title":"Arthritis Care Res."},{"issue":"5","key":"189_CR11","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1002\/art.30239","volume":"63","author":"CM Bartels","year":"2011","unstructured":"Bartels CM, Kind AJH, Everett C, Mell M, McBride P, Smith M. Low frequency of primary lipid screening among Medicare patients with rheumatoid arthritis. Arthritis Rheumatol. 2011;63(5):1221\u201330.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"189_CR12","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13075-019-1817-y","volume":"21","author":"OR Ghosh-Swaby","year":"2019","unstructured":"Ghosh-Swaby OR, Kuriya B. Awareness and perceived risk of cardiovascular disease among individuals living with rheumatoid arthritis is low: results of a systematic literature review. Arthritis Res Ther. 2019;21(1):33.","journal-title":"Arthritis Res Ther."},{"key":"189_CR13","unstructured":"Hochberg MC, Gravallese EM, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH. Rheumatology. 7th Edition. Philadelphia: Elsevier; 2019. Chapter 95: Extraarticular features of rheumatoid arthritis; 771\u2013772."},{"issue":"10","key":"189_CR14","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1016\/j.amjmed.2008.06.011","volume":"121","author":"SE Gabriel","year":"2008","unstructured":"Gabriel SE. Cardiovascular morbidity and mortality in rheumatoid arthritis. Am J Med. 2008;121(10):S9\u201314.","journal-title":"Am J Med"},{"issue":"12","key":"189_CR15","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1002\/art.24092","volume":"59","author":"JA Avi\u00f1a-Zubieta","year":"2008","unstructured":"Avi\u00f1a-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum. 2008;59(12):1690\u20137.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"189_CR16","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/art.33322","volume":"64","author":"AK Bacani","year":"2012","unstructured":"Bacani AK, Gabriel SE, Crowson CS, Heit JA, Matteson EL. Noncardiac vascular disease in rheumatoid arthritis: increase in venous thromboembolic events? Arthritis Rheum. 2012;64(1):53\u201361.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"189_CR17","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1136\/annrheumdis-2014-206879","volume":"75","author":"EEA Arts","year":"2016","unstructured":"Arts EEA, Popa CD, Den Broeder AA, Donders R, Sandoo A, Toms T, et al. Prediction of cardiovascular risk in rheumatoid arthritis: performance of original and adapted SCORE algorithms. Ann Rheum Dis. 2016;75(4):674\u201380.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"189_CR18","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.amjcard.2012.03.044","volume":"110","author":"CS Crowson","year":"2012","unstructured":"Crowson CS, Matteson EL, Roger VL, Therneau TM, Gabriel SE. Usefulness of risk scores to estimate the risk of cardiovascular disease in patients with rheumatoid arthritis. Am J Cardiol. 2012;110(3):420\u20134.","journal-title":"Am J Cardiol"},{"issue":"6","key":"189_CR19","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.107.699579","volume":"117","author":"RB D\u2019Agostino","year":"2008","unstructured":"D\u2019Agostino RB, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117(6):743\u201353.","journal-title":"Circulation"},{"issue":"10","key":"189_CR20","doi-asserted-by":"publisher","first-page":"3045","DOI":"10.1002\/art.21288","volume":"52","author":"CP Chung","year":"2005","unstructured":"Chung CP, Oeser A, Raggi P, Gebretsadik T, Shintani AK, Sokka T, et al. Increased coronary-artery atherosclerosis in rheumatoid arthritis: relationship to disease duration and cardiovascular risk factors. Arthritis Rheum. 2005;52(10):3045\u201353.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"189_CR21","doi-asserted-by":"publisher","first-page":"R36","DOI":"10.1186\/ar2641","volume":"11","author":"JT Giles","year":"2009","unstructured":"Giles JT, Szklo M, Post W, Petri M, Blumenthal RS, Lam G, et al. Coronary arterial calcification in rheumatoid arthritis: comparison with the Multi-Ethnic Study of Atherosclerosis. Arthritis Res Ther. 2009;11(2):R36.","journal-title":"Arthritis Res Ther."},{"issue":"10","key":"189_CR22","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1136\/annrheumdis-2013-203617","volume":"73","author":"GA Karpouzas","year":"2014","unstructured":"Karpouzas GA, Malpeso J, Choi T-Y, Li D, Munoz S, Budoff MJ. Prevalence, extent and composition of coronary plaque in patients with rheumatoid arthritis without symptoms or prior diagnosis of coronary artery disease. Ann Rheum Dis. 2014;73(10):1797\u2013804.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"189_CR23","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.jbspin.2010.07.016","volume":"78","author":"J-F Boyer","year":"2011","unstructured":"Boyer J-F, Gourraud P-A, Cantagrel A, Davignon J-L, Constantin A. Traditional cardiovascular risk factors in rheumatoid arthritis: a meta-analysis. Jt Bone Spine. 2011;78(2):179\u201383.","journal-title":"Jt Bone Spine."},{"issue":"2","key":"189_CR24","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.atherosclerosis.2007.01.004","volume":"196","author":"CP Chung","year":"2008","unstructured":"Chung CP, Oeser A, Solus JF, Avalos I, Gebretsadik T, Shintani A, et al. Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis. Atherosclerosis. 2008;196(2):756\u201363.","journal-title":"Atherosclerosis."},{"issue":"6","key":"189_CR25","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1136\/ard.2010.143396","volume":"70","author":"J Lindhardsen","year":"2011","unstructured":"Lindhardsen J, Ahlehoff O, Gislason GH, Madsen OR, Olesen JB, Torp-Pedersen C, et al. The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study. Ann Rheum Dis. 2011;70(6):929\u201334.","journal-title":"Ann Rheum Dis"},{"key":"189_CR26","doi-asserted-by":"crossref","unstructured":"L\u00f3pez-Longo FJ, Oliver-Mi\u00f1arro D, de la Torre I, Gonz\u00e1lez-D\u00edaz de R\u00e1bago E, S\u00e1nchez-Ram\u00f3n S, Rodr\u00edguez-Mahou M, et al. Association between anti-cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis. Arthritis Rheum. 2009;61(4):419\u201324.","DOI":"10.1002\/art.24390"},{"key":"189_CR27","doi-asserted-by":"crossref","unstructured":"Danesh J, Kaptoge S, Mann AG, Sarwar N, Wood A, Angleman SB, et al. Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. Baigent C, editor. PLoS Med. 2008;5(4):e78.","DOI":"10.1371\/journal.pmed.0050078"},{"issue":"15","key":"189_CR28","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1161\/01.CIR.101.15.1767","volume":"101","author":"PM Ridker","year":"2000","unstructured":"Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation. 2000;101(15):1767\u201372.","journal-title":"Circulation"},{"issue":"1","key":"189_CR29","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1002\/art.39419","volume":"68","author":"R Winchester","year":"2016","unstructured":"Winchester R, Giles JT, Nativ S, Downer K, Zhang H-Z, Bag-Ozbek A, et al. Association of elevations of specific T cell and monocyte subpopulations in rheumatoid arthritis with subclinical coronary artery atherosclerosis. Arthritis Rheumatol (Hoboken, NJ). 2016;68(1):92\u2013102.","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"issue":"16","key":"189_CR30","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1161\/01.CIR.0000125700.33637.B1","volume":"109","author":"T W\u00e6hre","year":"2004","unstructured":"W\u00e6hre T, Yndestad A, Smith C, Haug T, Tunheim SH, Gullestad L, et al. Increased Expression of interleukin-1 in coronary artery disease with downregulatory effects of HMG-CoA reductase inhibitors. Circulation. 2004;109(16):1966\u201372.","journal-title":"Circulation"},{"issue":"8","key":"189_CR31","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1161\/01.CIR.98.8.731","volume":"98","author":"PM Ridker","year":"1998","unstructured":"Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation. 1998;98(8):731\u20133.","journal-title":"Circulation"},{"issue":"8","key":"189_CR32","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1002\/art.21204","volume":"52","author":"NJ Goodson","year":"2005","unstructured":"Goodson NJ, Symmons DPM, Scott DGI, Bunn D, Lunt M, Silman AJ. Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year follow-up study of a primary care-based inception cohort. Arthritis Rheum. 2005;52(8):2293\u20139.","journal-title":"Arthritis Rheum"},{"key":"189_CR33","doi-asserted-by":"crossref","unstructured":"Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium, Swerdlow DI, Holmes MV, Kuchenbaecker KB, Engmann JEL, Shah T, et al. The interleukin-6 receptor as a target for prevention of coronary heart disease: a Mendelian randomisation analysis. Lancet. 2012;379(9822):1214\u201324.","DOI":"10.1016\/S0140-6736(12)60110-X"},{"issue":"7","key":"189_CR34","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1002\/art.11078","volume":"48","author":"I del Rinc\u00f3n","year":"2003","unstructured":"del Rinc\u00f3n I, Williams K, Stern MP, Freeman GL, O\u2019Leary DH, Escalante A. Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects: atherosclerosis and Inflammation Markers. Arthritis Rheum. 2003;48(7):1833\u201340.","journal-title":"Arthritis Rheum"},{"issue":"11","key":"189_CR35","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1002\/art.25009","volume":"61","author":"YH Rho","year":"2009","unstructured":"Rho YH, Chung CP, Oeser A, Solus J, Asanuma Y, Sokka T, et al. Inflammatory mediators and premature coronary atherosclerosis in rheumatoid arthritis. Arthritis Rheum. 2009;61(11):1580\u20135.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"189_CR36","doi-asserted-by":"publisher","first-page":"285","DOI":"10.2174\/157016110790886965","volume":"8","author":"M Cugno","year":"2010","unstructured":"Cugno M, Ingegnoli F, Gualtierotti R, Fantini F. Potential effect of anti-tumour necrosis factor-alpha treatment on reducing the cardiovascular risk related to rheumatoid arthritis. CVP. 2010;8(2):285\u201392.","journal-title":"CVP"},{"issue":"1","key":"189_CR37","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/1471-2407-9-40","volume":"9","author":"X Chang","year":"2009","unstructured":"Chang X, Han J, Pang L, Zhao Y, Yang Y, Shen Z. Increased PADI4 expression in blood and tissues of patients with malignant tumors. BMC Cancer. 2009;9(1):40.","journal-title":"BMC Cancer."},{"issue":"9","key":"189_CR38","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1002\/jnr.21329","volume":"85","author":"FG Mastronardi","year":"2007","unstructured":"Mastronardi FG, Noor A, Wood DD, Paton T, Moscarello MA. Peptidyl argininedeiminase 2 CpG island in multiple sclerosis white matter is hypomethylated. J Neurosci Res. 2007;85(9):2006\u201316.","journal-title":"J Neurosci Res"},{"issue":"1","key":"189_CR39","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1002\/jnr.20431","volume":"80","author":"A Ishigami","year":"2005","unstructured":"Ishigami A, Ohsawa T, Hiratsuka M, Taguchi H, Kobayashi S, Saito Y, et al. Abnormal accumulation of citrullinated proteins catalyzed by peptidylarginine deiminase in hippocampal extracts from patients with Alzheimer\u2019s disease. J Neurosci Res. 2005;80(1):120\u20138.","journal-title":"J Neurosci Res"},{"key":"189_CR40","doi-asserted-by":"crossref","unstructured":"Sokolove J, Bromberg R, Deane KD, Lahey LJ, Derber LA, Chandra PE, et al. Autoantibody Epitope Spreading in the Pre-Clinical Phase Predicts Progression to Rheumatoid Arthritis. Matloubian M, editor. PLoS ONE. 2012;7(5):e35296.","DOI":"10.1371\/journal.pone.0035296"},{"issue":"4","key":"189_CR41","doi-asserted-by":"publisher","first-page":"R128","DOI":"10.1186\/ar2017","volume":"8","author":"D Mewar","year":"2006","unstructured":"Mewar D, Coote A, Moore DJ, Marinou I, Keyworth J, Dickson MC, et al. Independent associations of anti-cyclic citrullinated peptide antibodies and rheumatoid factor with radiographic severity of rheumatoid arthritis. Arthritis Res Ther. 2006;8(4):R128.","journal-title":"Arthritis Res Ther."},{"issue":"7","key":"189_CR42","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1002\/art.37961","volume":"65","author":"J Sokolove","year":"2013","unstructured":"Sokolove J, Brennan MJ, Sharpe O, Lahey LJ, Kao AH, Krishnan E, et al. Brief report: citrullination within the atherosclerotic plaque: a potential target for the anti-citrullinated protein antibody response in rheumatoid arthritis. Arthritis Rheum. 2013;65(7):1719\u201324.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"189_CR43","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1002\/art.23284","volume":"58","author":"C Clavel","year":"2008","unstructured":"Clavel C, Nogueira L, Laurent L, Iobagiu C, Vincent C, Sebbag M, et al. Induction of macrophage secretion of tumor necrosis factor \u03b1 through Fc\u03b3 receptor IIa engagement by rheumatoid arthritis\u2013specific autoantibodies to citrullinated proteins complexed with fibrinogen. Arthritis Rheum. 2008;58(3):678\u201388.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"189_CR44","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/art.40345","volume":"70","author":"L Geraldino-Pardilla","year":"2018","unstructured":"Geraldino-Pardilla L, Zartoshti A, Ozbek AB, Giles JT, Weinberg R, Kinkhabwala M, et al. Arterial inflammation detected With 18 F-fluorodeoxyglucose-positron emission tomography in rheumatoid arthritis. Arthritis Rheumatol. 2018;70(1):30\u20139.","journal-title":"Arthritis Rheumatol."},{"issue":"2","key":"189_CR45","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1002\/art.20855","volume":"52","author":"PJ Nicola","year":"2005","unstructured":"Nicola PJ, Maradit-Kremers H, Roger VL, Jacobsen SJ, Crowson CS, Ballman KV, et al. The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years. Arthritis Rheum. 2005;52(2):412\u201320.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"189_CR46","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1002\/art.23798","volume":"58","author":"JM Davis","year":"2008","unstructured":"Davis JM, Roger VL, Crowson CS, Kremers HM, Therneau TM, Gabriel SE. The presentation and outcome of heart failure in patients with rheumatoid arthritis differs from that in the general population. Arthritis Rheum. 2008;58(9):2603\u201311.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"189_CR47","doi-asserted-by":"publisher","first-page":"R39","DOI":"10.1186\/ar3752","volume":"14","author":"JT Giles","year":"2012","unstructured":"Giles JT, Fert-Bober J, Park J, Bingham CO, Andrade F, Fox-Talbot K, et al. Myocardial citrullination in rheumatoid arthritis: a correlative histopathologic study. Arthritis Res Ther. 2012;14(1):R39.","journal-title":"Arthritis Res Ther."},{"issue":"7\u20138","key":"189_CR48","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1002\/prca.201400013","volume":"8","author":"J Fert-Bober","year":"2014","unstructured":"Fert-Bober J, Sokolove J. Proteomics of citrullination in cardiovascular disease. Prot Clin Appl. 2014;8(7\u20138):522\u201333.","journal-title":"Prot Clin Appl"},{"key":"189_CR49","doi-asserted-by":"crossref","unstructured":"Geraldino-Pardilla L, Russo C, Sokolove J, Robinson WH, Zartoshti A, Van Eyk J, et al. Association of anti-citrullinated protein or peptide antibodies with left ventricular structure and function in rheumatoid arthritis. Rheumatology (Oxford). 2017;56(4):534\u201340.","DOI":"10.1093\/rheumatology\/kew436"},{"key":"189_CR50","doi-asserted-by":"crossref","unstructured":"Anderson DR, Duryee MJ, Shurmur SW, Um JY, Bussey WD, Hunter CD, et al. Unique antibody responses to malondialdehyde-acetaldehyde (MAA)-protein adducts predict coronary artery disease. Obukhov AG, editor. PLoS ONE. 2014;9(9):e107440.","DOI":"10.1371\/journal.pone.0107440"},{"issue":"3","key":"189_CR51","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1002\/art.38969","volume":"67","author":"GM Thiele","year":"2015","unstructured":"Thiele GM, Duryee MJ, Anderson DR, Klassen LW, Mohring SM, Young KA, et al. Malondialdehyde-acetaldehyde adducts and anti-malondialdehyde-acetaldehyde antibodies in rheumatoid arthritis. Arthritis Rheumatol (Hoboken, NJ). 2015;67(3):645\u201355.","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"issue":"1","key":"189_CR52","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13075-015-0536-2","volume":"17","author":"M Brink","year":"2015","unstructured":"Brink M, Verheul MK, R\u00f6nnelid J, Berglin E, Holmdahl R, Toes R, et al. Anti-carbamylated protein antibodies in the pre-symptomatic phase of rheumatoid arthritis, their relationship with multiple anti-citrulline peptide antibodies and association with radiological damage. Arthritis Res Ther. 2015;17(1):25.","journal-title":"Arthritis Res Ther."},{"key":"189_CR53","doi-asserted-by":"crossref","unstructured":"Spinelli FR, Pecani A, Conti F, Mancini R, Alessandri C, Valesini G. Post-translational modifications in rheumatoid arthritis and atherosclerosis: focus on citrullination and carbamylation. J Int Med Res. 2016;44(1_suppl):81\u20134.","DOI":"10.1177\/0300060515593258"},{"issue":"1","key":"189_CR54","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/s12891-017-1563-8","volume":"18","author":"FR Spinelli","year":"2017","unstructured":"Spinelli FR, Pecani A, Ciciarello F, Colasanti T, Di Franco M, Miranda F, et al. Association between antibodies to carbamylated proteins and subclinical atherosclerosis in rheumatoid arthritis patients. BMC Musculoskelet Disord. 2017;18(1):214.","journal-title":"BMC Musculoskelet Disord."},{"key":"189_CR55","doi-asserted-by":"crossref","unstructured":"Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum. 1987;30(11):1205\u201313.","DOI":"10.1002\/art.1780301102"},{"issue":"6","key":"189_CR56","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1002\/art.1780390606","volume":"39","author":"I Waase","year":"1996","unstructured":"Waase I, Kayser C, Carlson PJ, Goronzy JJ, Weyand CM. Oligoclonal T cell proliferation in patients with rheumatoid arthritis and their unaffected siblings. Arthritis Rheum. 1996;39(6):904\u201313.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"189_CR57","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1002\/art.1780400615","volume":"40","author":"PB Martens","year":"1997","unstructured":"Martens PB, Goronzy JJ, Schaid D, Weyand CM. Expansion of unusual CD4\u2009+\u2009T cells in severe rheumatoid arthritis. Arthritis Rheum. 1997;40(6):1106\u201314.","journal-title":"Arthritis Rheum"},{"issue":"22","key":"189_CR58","doi-asserted-by":"publisher","first-page":"2744","DOI":"10.1161\/01.CIR.0000131450.66017.B3","volume":"109","author":"R Gerli","year":"2004","unstructured":"Gerli R, Schillaci G, Giordano A, Bocci EB, Bistoni O, Vaudo G, et al. CD4\u2009+\u2009CD28- T lymphocytes contribute to early atherosclerotic damage in rheumatoid arthritis patients. Circulation. 2004;109(22):2744\u20138.","journal-title":"Circulation"},{"issue":"25","key":"189_CR59","doi-asserted-by":"publisher","first-page":"2883","DOI":"10.1161\/01.CIR.101.25.2883","volume":"101","author":"G Liuzzo","year":"2000","unstructured":"Liuzzo G, Goronzy JJ, Yang H, Kopecky SL, Holmes DR, Frye RL, et al. Monoclonal T-cell proliferation and plaque instability in acute coronary syndromes. Circulation. 2000;101(25):2883\u20138.","journal-title":"Circulation"},{"issue":"5","key":"189_CR60","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1161\/hc0502.103348","volume":"105","author":"T Nakajima","year":"2002","unstructured":"Nakajima T, Schulte S, Warrington KJ, Kopecky SL, Frye RL, Goronzy JJ, et al. T-cell\u2013mediated lysis of endothelial cells in acute coronary syndromes. Circulation. 2002;105(5):570\u20135.","journal-title":"Circulation"},{"issue":"2","key":"189_CR61","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1161\/01.RES.0000082333.58263.58","volume":"93","author":"T Nakajima","year":"2003","unstructured":"Nakajima T, Goek \u00d6, Zhang X, Kopecky SL, Frye RL, Goronzy JJ, et al. De novo expression of killer immunoglobulin-like receptors and signaling proteins regulates the cytotoxic function of CD4 T cells in acute coronary syndromes. Circ Res. 2003;93(2):106\u201313.","journal-title":"Circ Res"},{"key":"189_CR62","unstructured":"Treatments Against RA and Effects on FDG-PET\/CT. [cited 2016 3\/13\/2016] ClinicalTrialsgov [Internet]. 2019. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02374021."},{"key":"189_CR63","doi-asserted-by":"crossref","unstructured":"Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS, et al. Rheumatoid arthritis. Nat Rev Dis Primers. 2018;4(1):18001.","DOI":"10.1038\/nrdp.2018.1"},{"issue":"10","key":"189_CR64","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1136\/annrheumdis-2015-207870","volume":"75","author":"J Zhang","year":"2016","unstructured":"Zhang J, Xie F, Yun H, Chen L, Muntner P, Levitan EB, et al. Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis. Ann Rheum Dis. 2016;75(10):1813\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"189_CR65","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.semarthrit.2018.03.012","volume":"48","author":"SC Kim","year":"2018","unstructured":"Kim SC, Solomon DH, Rogers JR, Gale S, Klearman M, Sarsour K, et al. No difference in cardiovascular risk of tocilizumab versus abatacept for rheumatoid arthritis: a multi-database cohort study. Semin Arthritis Rheum. 2018;48(3):399\u2013405.","journal-title":"Semin Arthritis Rheum"},{"key":"189_CR66","doi-asserted-by":"crossref","unstructured":"Singh S, Fumery M, Singh AG, Singh N, Prokop LJ, Dulai PS, et al. Comparative risk of cardiovascular events with biologic and synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res. 2019;acr.23875.","DOI":"10.1002\/acr.23875"},{"issue":"4","key":"189_CR67","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1002\/art.40771","volume":"71","author":"I Amigues","year":"2019","unstructured":"Amigues I, Tugcu A, Russo C, Giles JT, Morgenstein R, Zartoshti A, et al. Myocardial inflammation, measured using 18-fluorodeoxyglucose positron emission tomography with computed tomography, is associated with disease activity in rheumatoid arthritis. Arthritis Rheumatol. 2019;71(4):496\u2013506.","journal-title":"Arthritis Rheumatol."},{"key":"189_CR68","doi-asserted-by":"crossref","unstructured":"del Inmaculada R, Battafarano DF, Restrepo JF, Erikson JM, Escalante A. Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis. Arthritis Rheumatol (Hoboken, N.J.) 2014;66(2):264\u201372.","DOI":"10.1002\/art.38210"},{"key":"189_CR69","doi-asserted-by":"crossref","unstructured":"Roubille C, Vincent R, Tara S, Collette M, Alexandra M, Patrick F, Stephanie S et al. The Effects of Tumour Necrosis Factor Inhibitors, Methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheumatic Dis. 2015;74(3):480\u201389.","DOI":"10.1136\/annrheumdis-2014-206624"},{"issue":"5","key":"189_CR70","doi-asserted-by":"publisher","first-page":"467","DOI":"10.3899\/jrheum.180427","volume":"46","author":"J Widdifield","year":"2019","unstructured":"Widdifield J, Abrahamowicz M, Paterson JM, Huang A, Thorne JC, Pope JE, et al. Associations between methotrexate use and the risk of cardiovascular events in patients with elderly-onset rheumatoid arthritis. J Rheumatol. 2019;46(5):467\u201374.","journal-title":"J Rheumatol"},{"key":"189_CR71","doi-asserted-by":"crossref","unstructured":"Micha R, Imamura F, Wyler von Ballmoos M, Solomon DH, Hern\u00e1n MA, Ridker PM, et al. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol. 2011;108(9):1362\u201370.","DOI":"10.1016\/j.amjcard.2011.06.054"},{"issue":"3","key":"189_CR72","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1002\/art.39502","volume":"68","author":"C Charles-Schoeman","year":"2016","unstructured":"Charles-Schoeman C, Wang X, Lee YY, Shahbazian A, Navarro-Mill\u00e1n I, Yang S, et al. Association of triple therapy with improvement in cholesterol profiles over two-year follow-up in the treatment of early aggressive rheumatoid arthritis trial: triple therapy and cholesterol profiles in early RA. Arthritis Rheumatol. 2016;68(3):577\u201386.","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"189_CR73","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1517\/14656566.9.7.1121","volume":"9","author":"J Avouac","year":"2008","unstructured":"Avouac J, Allanore Y. Cardiovascular risk in rheumatoid arthritis: effects of anti-TNF drugs. Exp Opin Pharmacother. 2008;9(7):1121\u20138.","journal-title":"Exp Opin Pharmacother"},{"issue":"1","key":"189_CR74","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1080\/03009740802363768","volume":"38","author":"PI Sidiropoulos","year":"2009","unstructured":"Sidiropoulos PI, Siakka P, Pagonidis K, Raptopoulou A, Kritikos H, Tsetis D, et al. Sustained improvement of vascular endothelial function during anti-TNF\u03b1 treatment in rheumatoid arthritis patients. Scand J Rheumatol. 2009;38(1):6\u201310.","journal-title":"Scand J Rheumatol"},{"issue":"4","key":"189_CR75","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1002\/acr.20371","volume":"63","author":"C Barnabe","year":"2011","unstructured":"Barnabe C, Martin B-J, Ghali WA. Systematic review and meta-analysis: anti-tumor necrosis factor \u03b1 therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res. 2011;63(4):522\u20139.","journal-title":"Arthritis Care Res."},{"issue":"12","key":"189_CR76","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1136\/annrheumdis-2015-208995","volume":"75","author":"L Ljung","year":"2016","unstructured":"Ljung L, Rantap\u00e4\u00e4-Dahlqvist S, Jacobsson LTH, Askling J. Response to biological treatment and subsequent risk of coronary events in rheumatoid arthritis. Ann Rheum Dis. 2016;75(12):2087\u201394.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"189_CR77","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.3899\/jrheum.170926","volume":"45","author":"Y Jin","year":"2018","unstructured":"Jin Y, Kang EH, Brill G, Desai RJ, Kim SC. Cardiovascular (CV) risk after initiation of abatacept versus TNF inhibitors in rheumatoid arthritis patients with and without baseline CV disease. J Rheumatol. 2018;45(9):1240\u20138.","journal-title":"J Rheumatol"},{"issue":"5","key":"189_CR78","doi-asserted-by":"publisher","first-page":"R141","DOI":"10.1186\/ar3455","volume":"13","author":"MH Schiff","year":"2011","unstructured":"Schiff MH, Kremer JM, Jahreis A, Vernon E, Isaacs JD, van Vollenhoven RF. Integrated safety in tocilizumab clinical trials. Arthritis Res Ther. 2011;13(5):R141.","journal-title":"Arthritis Res Ther."},{"issue":"01","key":"189_CR79","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1136\/ard.2008.105197","volume":"69","author":"G Jones","year":"2010","unstructured":"Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010;69(01):88\u201396.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"189_CR80","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1136\/annrheumdis-2013-204345","volume":"74","author":"IB McInnes","year":"2015","unstructured":"McInnes IB, Thompson L, Giles JT, Bathon JM, Salmon JE, Beaulieu AD, et al. Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: mEASURE, a randomised, placebo-controlled study. Ann Rheum Dis. 2015;74(4):694\u2013702.","journal-title":"Ann Rheum Dis"},{"key":"189_CR81","doi-asserted-by":"crossref","unstructured":"Fleischmann R, Genovese MC, Lin Y, St John G, van der Heijde D, Wang S, et al. Long-term safety of sarilumab in rheumatoid arthritis: an integrated analysis with up to 7\u00a0years\u2019 follow-up. Rheumatology. 2019;kez265.","DOI":"10.1093\/rheumatology\/kez265"},{"issue":"20","key":"189_CR82","doi-asserted-by":"publisher","first-page":"2662","DOI":"10.1161\/CIRCULATIONAHA.107.731877","volume":"117","author":"I Ikonomidis","year":"2008","unstructured":"Ikonomidis I, Lekakis JP, Nikolaou M, Paraskevaidis I, Andreadou I, Kaplanoglou T, et al. Inhibition of interleukin-1 by Anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis. Circulation. 2008;117(20):2662\u20139.","journal-title":"Circulation"},{"key":"189_CR83","doi-asserted-by":"crossref","unstructured":"van Vollenhoven RF, Emery P, Bingham CO, Keystone EC, Fleischmann RM, Furst DE, et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis. 2013;72(9):1496\u2013502.","DOI":"10.1136\/annrheumdis-2012-201956"},{"issue":"12","key":"189_CR84","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119\u201331.","journal-title":"N Engl J Med"},{"key":"189_CR85","doi-asserted-by":"crossref","unstructured":"Giles JT, Sattar N, Gabriel S, Ridker PM, Gay S, Warne C, et al. Cardiovascular safety of tocilizumab versus etanercept in rheumatoid arthritis: a randomized controlled trial. Arthritis Rheumatol. 2019;art.41095.","DOI":"10.1002\/art.41095"},{"key":"189_CR86","doi-asserted-by":"crossref","unstructured":"Tanaka Y, Suzuki M, Nakamura H, Toyoizumi S, Zwillich SH, Tofacitinib Study Investigators. Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res. 2011;63(8):1150\u20138.","DOI":"10.1002\/acr.20494"},{"issue":"3","key":"189_CR87","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.semarthrit.2016.05.014","volume":"46","author":"C Charles-Schoeman","year":"2016","unstructured":"Charles-Schoeman C, Wicker P, Gonzalez-Gay MA, Boy M, Zuckerman A, Soma K, et al. Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor. Semin Arthritis Rheum. 2016;46(3):261\u201371.","journal-title":"Semin Arthritis Rheum"},{"issue":"9","key":"189_CR88","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1002\/art.40911","volume":"71","author":"C Charles-Schoeman","year":"2019","unstructured":"Charles-Schoeman C, DeMasi R, Valdez H, Soma K, Hwang L, Boy MG, et al. Risk factors for major adverse cardiovascular events in phase III and long-term extension studies of tofacitinib in patients with rheumatoid arthritis. Arthritis Rheumatol. 2019;71(9):1450\u20139.","journal-title":"Arthritis Rheumatol."},{"key":"189_CR89","unstructured":"Safety Study of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor in Subjects with Rheumatoid Arthritis [cited 2014 4\/20\/2014] ClinicalTrialsgov [Internet] 2019. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02092467."},{"issue":"7","key":"189_CR90","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1002\/art.40841","volume":"71","author":"PC Taylor","year":"2019","unstructured":"Taylor PC, Weinblatt ME, Burmester GR, Rooney TP, Witt S, Walls CD, et al. Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis. Arthritis Rheumatol (Hoboken, NJ). 2019;71(7):1042\u201355.","journal-title":"Arthritis Rheumatol (Hoboken, NJ)."}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-019-00189-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-019-00189-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-019-00189-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T17:22:02Z","timestamp":1715188922000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-019-00189-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,18]]},"references-count":90,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["189"],"URL":"https:\/\/doi.org\/10.1007\/s40744-019-00189-0","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,18]]},"assertion":[{"value":"29 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}